Corticotropin
- Generic Name
- Corticotropin
- Brand Names
- Acthar, Cortrophin
- Drug Type
- Biotech
- CAS Number
- 12427-33-7
- Unique Ingredient Identifier
- K0U68Q2TXA
- Background
Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
- Indication
For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
Purified corticotropin for injection is indicated for a variety of allergic and autoimmune conditions.
- Associated Conditions
- Acute Gouty Arthritis, Allergic Conjunctivitis (AC), Ankylosing Spondylitis (AS), Atopic Dermatitis, Chorioretinitis, Choroiditis, Infantile Spasms (IS), Iridocyclitis, Iritis, Keratitis, Multiple sclerosis exacerbation, Optic Neuritis, Polymyositis, Psoriatic Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Serum Sickness, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Anterior eye segment inflammation, Severe Erythema multiforme, Severe Psoriasis, Symptomatic Sarcoidosis, Systemic Dermatomyositis
Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Aaron Miller
- Target Recruit Count
- 10
- Registration Number
- NCT01900093
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2014-09-16
- Target Recruit Count
- 25
- Registration Number
- NCT01888354
- Locations
- 🇺🇸
The MS Center at the Neurology Center in Southern California, Oceanside, California, United States
🇺🇸The University of Texas-Houston Neurology Clinic, Houston, Texas, United States
A Trial of Neuroprotection With ACTH in Acute Optic Neuritis
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 37
- Registration Number
- NCT01838174
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States
A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Dent Neuroscience Research Center
- Target Recruit Count
- 20
- Registration Number
- NCT01813591
- Locations
- 🇺🇸
Renown Institute of Neurosciences, Reno, Nevada, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇺🇸Dent Neurologic Institute, Amherst, New York, United States
Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus
- Conditions
- Lupus Erythematosus Systemic Exacerbation
- Interventions
- First Posted Date
- 2013-01-17
- Last Posted Date
- 2013-07-23
- Lead Sponsor
- Fiechtner, Justus J., M.D., P.C.
- Target Recruit Count
- 10
- Registration Number
- NCT01769937
- Locations
- 🇺🇸
Justus J. Fiechtner, Lansing, Michigan, United States
Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- First Posted Date
- 2012-12-20
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 38
- Registration Number
- NCT01753401
- Locations
- 🇺🇸
Mallinckrodt Investigational Site, Houston, Texas, United States
Dermatomyositis and Polymyositis Registry
- Conditions
- DermatomyositisPolymyositis
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2015-11-06
- Lead Sponsor
- Phoenix Neurological Associates, LTD
- Target Recruit Count
- 100
- Registration Number
- NCT01637064
- Locations
- 🇺🇸
PNA Center for Neurological Research, Phoenix, Arizona, United States
🇺🇸Neurology INC, Columbia, Missouri, United States
🇺🇸New York Methodist Hospital, Brooklyn, New York, United States
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
- Conditions
- Diabetic Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 34
- Registration Number
- NCT01601236
- Locations
- 🇺🇸
Questcor Investigational Site, San Antonio, Texas, United States
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
- Conditions
- Idiopathic Membranous NephropathyProteinuria
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 60
- Registration Number
- NCT01386554
- Locations
- 🇲🇽
Mallinckrodt Investigational Site, San Nicolas de los Garza, Nuevo Leon, Mexico
🇹🇷Mallinckrodt Investigational Site 307, Adana, Turkey
🇹🇷Mallinckrodt Investigational Site 301, Istanbul, Turkey
Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 15
- Registration Number
- NCT01155141
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.